# EDGAR Filing Document

**Accession Number:** 0001582384
**File Stem:** 0001021408-25-000429
**Filing Date:** 2025-7
**Character Count:** 5215
**Document Hash:** fbf262de554bcb7ec788594deb0f6893
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001021408-25-000429.hdr.sgml**: 20250715

**ACCESSION NUMBER**: 0001021408-25-000429

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250715

**EFFECTIVENESS DATE**: 20250715

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Wildcat Capital Management, LLC
- **CENTRAL INDEX KEY:** 0001582384

**ORGANIZATION NAME:**
- **EIN:** 453715536
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1213

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-16579
- **FILM NUMBER:** 251123541

**BUSINESS ADDRESS:**
- **STREET 1:** 888 SEVENTH AVENUE
- **STREET 2:** 37TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10106
- **BUSINESS PHONE:** 212-468-5100

**MAIL ADDRESS:**
- **STREET 1:** 888 SEVENTH AVENUE
- **STREET 2:** 37TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10106

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001582384

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Wildcat Capital Management, LLC

**Address:** 888 Seventh Avenue, 37th Floor, New York, NY 10106

**Telephone number:** 212-468-5100

**Name of agent for service:** Brian J. Rosenblatt

**Agent Address:** 888 Seventh Avenue, 37th Floor, New York, NY 10106

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-16579

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                | CUSIP   | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                        | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Urogen Pharma Ltd             | M96088  | 08/06/2024     | To approve the Company's 2024 non-employee director and officer compensation policy.                                                                                    | SECTION 14A SAY-ON-PAY VOTES |         495606 |                0 | ABSTAIN     |                                   495606 | NONE                        |  |
| Urogen Pharma Ltd             | M96088  | 08/06/2024     | To approve an amendment to the Company's 2017 Equity Incentive Plan to increase the number of ordinary shares authorized for issuance under the plan by 800,000 shares. | SECTION 14A SAY-ON-PAY VOTES |         495606 |                0 | ABSTAIN     |                                   495606 | NONE                        |  |
| Urogen Pharma Ltd             | M96088  | 08/06/2024     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                           | SECTION 14A SAY-ON-PAY VOTES |         495606 |                0 | ABSTAIN     |                                   495606 | NONE                        |  |
| Frontier Group Holdings, Inc. | 35909R  | 05/14/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                           | SECTION 14A SAY-ON-PAY VOTES |       28061351 |                0 | ABSTAIN     |                                 28061351 | NONE                        |  |
| Allogene Therapeutics, Inc.   | 019770  | 06/17/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                           | SECTION 14A SAY-ON-PAY VOTES |        2920787 |                0 | ABSTAIN     |                                  2920787 | NONE                        |  |

## N-PX: Signature Block

**Reporting Person:** Wildcat Capital Management, LLC

**By (Signature):** Brian J. Rosenblatt

**By (Printed Signature):** Brian J. Rosenblatt

**By (Title):** General Counsel and Chief Operating Officer

**Date:** 07/15/2025